Global Ceftazidime and Avibactam Sodium for Injection Market Growth 2024-2030

Global Ceftazidime and Avibactam Sodium for Injection Market Growth 2024-2030

Ceftazidime and Avibactam Sodium for Injection is a fixed-dose combination medication composed of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor. It is used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia. It is given by injection into a vein. Ceftazidime is a cephalosporin antibiotic that works by stopping the growth of bacteria. Avibactam is an enzyme inhibitor (beta-lactamase inhibitor) that helps ceftazidime work better. This antibiotic treats only bacterial infections.

The global Ceftazidime and Avibactam Sodium for Injection market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Ceftazidime and Avibactam Sodium for Injection Industry Forecast” looks at past sales and reviews total world Ceftazidime and Avibactam Sodium for Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Ceftazidime and Avibactam Sodium for Injection sales for 2024 through 2030. With Ceftazidime and Avibactam Sodium for Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ceftazidime and Avibactam Sodium for Injection industry.

This Insight Report provides a comprehensive analysis of the global Ceftazidime and Avibactam Sodium for Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ceftazidime and Avibactam Sodium for Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ceftazidime and Avibactam Sodium for Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ceftazidime and Avibactam Sodium for Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ceftazidime and Avibactam Sodium for Injection.

United States market for Ceftazidime and Avibactam Sodium for Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Ceftazidime and Avibactam Sodium for Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Ceftazidime and Avibactam Sodium for Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Ceftazidime and Avibactam Sodium for Injection players cover Pfizer, Allergan (AbbVie), Sichuan Kelun Pharmaceutical, QILU Pharmaceutical and Nanjing YOKO Pharmaceutical. etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Ceftazidime and Avibactam Sodium for Injection market by product type, application, key manufacturers and key regions and countries.

Segmentation by type
Powders
Injections

Segmentation by application
Complicated Intra-Abdominal Infections (cIAI)
(HABP/VABP)
Complicated Urinary Tract Infections (cUTI)

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Allergan (AbbVie)
Sichuan Kelun Pharmaceutical
QILU Pharmaceutical
Nanjing YOKO Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Ceftazidime and Avibactam Sodium for Injection market?

What factors are driving Ceftazidime and Avibactam Sodium for Injection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Ceftazidime and Avibactam Sodium for Injection market opportunities vary by end market size?

How does Ceftazidime and Avibactam Sodium for Injection break out type, application?

Please note: The report will take approximately 2 business days to prepare and deliver.